Schlusskurs
Andere Börsenplätze
|
||
- USD | - |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | - |
Chief Operating Officer | - | 01.06.18 | |
Steven Klayman
PRN | Corporate Officer/Principal | - | - |
Mostafa Abuzeid
PRN | Corporate Officer/Principal | - | - |
Hans Christinger
PRN | Corporate Officer/Principal | - | - |
Gilbert Jaoudé
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 3 204 401 | 2 483 540 ( 77,50 %) | 0 | 77,50 % |
Unternehmenskontakt
Innovus Pharmaceuticals, Inc.
373 Inverness Parkway Suite 206
80112, Englewood
+858-964-5123
http://www.innovuspharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+45,82 % | 765 Mrd. | |
-6,16 % | 354 Mrd. | |
+19,86 % | 331 Mrd. | |
+9,32 % | 299 Mrd. | |
+18,91 % | 248 Mrd. | |
-1,72 % | 219 Mrd. | |
+11,10 % | 216 Mrd. | |
+5,90 % | 164 Mrd. | |
-0,73 % | 162 Mrd. |